InojosaHProschmannUAkgünK, et al. A focus on secondary progressive multiple sclerosis (SPMS): Challenges in diagnosis and definition. J Neurol. Epub ahead of print 30 July 2019. DOI: 10.1007/s00415-019-09489-5.
2.
RojasJIPatruccoLAlonsoR, et al. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis: Multicenter study in Argentina. Mult Scler2021; 27(4): 579–584.
3.
Katz SandIKriegerSFarrellC, et al. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler2013; 20(12): 1654–1657.
4.
ZiemssenTPiani-MeierDBennettB, et al. A physician-completed digital tool for evaluating disease progression (multiple sclerosis progression discussion tool): Validation study. J Med Internet Res2020; 22(2): e16932.
5.
SkoogBTedeholmHRunmarkerB, et al. Continuous prediction of secondary progression in the individual course of multiple sclerosis. Mult Scler Relat Disord2014; 3(5): 584–592.
6.
ManouchehriniaAZhuFPiani-MeierD, et al. Predicting risk of secondary progression in multiple sclerosis: A nomogram. Mult Scler2018; 25(8): 1102–1112.
7.
TolleyCPiani-MeierDBentleyS, et al. A novel, integrative approach for evaluating progression in multiple sclerosis: Development of a scoring algorithm. JMIR Med Inform2020; 8(4): e17592.
8.
ZiemssenTKernRCornelissenC.Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod. BMC Neurol2016; 16(1): 129.
9.
ZiemssenTHoffmannOKlotzL, et al. Study protocol of AMASIA, a non-interventional study to gain first insights on SPMS patients treated with siponimod in clinical routine. JMIR Res Protoc. Epub ahead of print 4 June 2020. DOI: 10.2196/19598.
